← Leaderboards
John M Maris
Children'S Hosp Of Philadelphia
$30,818,378
Attributed
$34,145,305
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $17.8M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$63,061,553 · 20
By mechanism
P01$18,072,872 · 5
U54$14,575,181 · 3
R01$12,420,271 · 4
R35$7,680,647 · 1
U01$4,740,245 · 2
T32$3,796,746 · 1
Top collaborators
- A Thomas Look5 shared
- Crystal Mackall4 shared
- Stephen Philip Schoenberger4 shared
- Robert C Seeger3 shared
- Crystal L Mackall2 shared
- William A Weiss2 shared
- Kevin A Cassady1 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Crystal Mackall$19,988,621
Others in their field
Top investigators on “Neuroblastoma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Gregory H Reaman · National Childhood Cancer Foundation$84,462,747
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$58,436,699
- Larry Arthur$30,516,306
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
NeuroblastomaChildMalignant Childhood NeoplasmHigh RiskTumorDesignMalignant NeoplasmsMissionUnited States National Institutes Of HealthProgramsTranslatingResistanceClinical TrialsMorbidity - Disease RateOncogenicRelapsePublic HealthBaseTumorigenesisEvidence BaseImmunotherapySympathetic Nervous SystemNovel TherapeuticsNeoplastic Cell
Grant awards (91)
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,447,225
P01 · FY2025 · CA · contact PI
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes$1,068,000
R35 · FY2025 · CA · contact PI
Personalized neuroblastoma vaccines$809,608
U01 · FY2025 · CA · contact PI
NextGen - CHOP$452,749
OT2 · FY2025 · CA · contact PI
Administrative Core$407,870
P01 · FY2025 · CA · contact PI
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,545,516
P01 · FY2024 · CA · contact PI
Personalized neuroblastoma vaccines$777,310
U01 · FY2024 · CA · contact PI
NextGen - CHOP$354,050
OT2 · FY2024 · CA · contact PI
Personalized neoantigen vaccines using nucleoside-modified mRNA-lipid nanoparticles$178,000
U01 · FY2024 · CA · contact PI
Administrative Core$114,553
P01 · FY2024 · CA · contact PI
Personalized neuroblastoma vaccines$839,128
U01 · FY2023 · CA · contact PI
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes$821,084
R35 · FY2023 · CA · contact PI
NextGen - CHOP$537,702
OT2 · FY2023 · CA · contact PI
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes$1,011,360
R35 · FY2022 · CA · contact PI
NextGen - CHOP$430,950
OT2 · FY2022 · CA · contact PI
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers$264,000
U54 · FY2022 · CA · contact PI
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers$255,100
U54 · FY2022 · CA · contact PI
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,085,090
P01 · FY2021 · CA · contact PI
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes$1,032,000
R35 · FY2021 · CA · contact PI
Proj 2 - Exploiting Therapeutic Vulnerabilities$355,201
P01 · FY2021 · CA
Pediatric Preclinical Testing Consortium$180,518
U01 · FY2021 · CA · contact PI
Engaging and Enhancing Neuroblastoma Immune Targeting$173,248
U54 · FY2021 · CA · contact PI
Proj 4 - Enhancing the Potency and Durability of Immunotherapies$122,203
P01 · FY2021 · CA
Administrative Core$82,580
P01 · FY2021 · CA · contact PI
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,218,284
P01 · FY2020 · CA · contact PI
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes$1,032,000
R35 · FY2020 · CA · contact PI
Proj 2 - Exploiting Therapeutic Vulnerabilities$386,498
P01 · FY2020 · CA
Administrative and Statistical Core Resource$184,000
U54 · FY2020 · CA · contact PI
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers$184,000
U54 · FY2020 · CA · contact PI
Pediatric Preclinical Testing Consortium$181,391
U01 · FY2020 · CA · contact PI
Proj 4 - Enhancing the Potency and Durability of Immunotherapies$152,924
P01 · FY2020 · CA
Administrative Core$91,541
P01 · FY2020 · CA · contact PI
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,078,428
P01 · FY2019 · CA
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes$1,001,040
R35 · FY2019 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$588,631
R01 · FY2019 · CA · contact PI
Pediatric Preclinical Testing Consortium$346,290
U01 · FY2019 · CA · contact PI
Administrative Core$92,889
P01 · FY2019 · CA · contact PI
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers$12,197,183
U54 · FY2018 · CA · contact PI
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,171,238
P01 · FY2018 · CA
Discovery and development of lineage-restricted pediatric cancer surfaceome immunotherapeutic targets$1,223,848
U54 · FY2018 · CA · contact PI
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes$1,032,000
R35 · FY2018 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$606,838
R01 · FY2018 · CA · contact PI
Pediatric Preclinical Testing Consortium$357,000
U01 · FY2018 · CA · contact PI
Administrative Core$95,762
P01 · FY2018 · CA · contact PI
Administrative and Statistical Core Resource$93,802
U54 · FY2018 · CA · contact PI
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance$2,296,936
P01 · FY2017 · CA
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes$683,163
R35 · FY2017 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$614,290
R01 · FY2017 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$606,838
R01 · FY2017 · CA · contact PI
Cancer Center Research Training Program$401,365
T32 · FY2017 · CA · contact PI
Pediatric Preclinical Testing Consortium$357,000
U01 · FY2017 · CA · contact PI
Administrative Core$328,134
P01 · FY2017 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$614,290
R01 · FY2016 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$606,838
R01 · FY2016 · CA · contact PI
Cancer Center Research Training Program$398,438
T32 · FY2016 · CA · contact PI
Pediatric Preclinical Testing Consortium$357,000
U01 · FY2016 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$623,838
R01 · FY2015 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$614,290
R01 · FY2015 · CA · contact PI
Cancer Center Research Training Program$398,967
T32 · FY2015 · CA · contact PI
Pediatric Preclinical Testing Consortium$357,000
U01 · FY2015 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$562,701
R01 · FY2014 · CA · contact PI
Cancer Center Research Training Program$380,039
T32 · FY2014 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$630,730
R01 · FY2013 · CA · contact PI
Cancer Center Research Training Program$379,946
T32 · FY2013 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$602,864
R01 · FY2012 · CA · contact PI
Cancer Center Research Training Program$387,028
T32 · FY2012 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$625,023
R01 · FY2011 · CA · contact PI
Cancer Center Research Training Program$376,072
T32 · FY2011 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$667,730
R01 · FY2010 · CA · contact PI
Cancer Center Research Training Program$357,463
T32 · FY2010 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$666,482
R01 · FY2009 · CA · contact PI
Cancer center research training program$358,223
T32 · FY2009 · CA · contact PI
The Genetic Basis of Neuroblastoma Tumorigenesis$675,621
R01 · FY2008 · CA · contact PI
Cancer center research training program$359,205
T32 · FY2008 · CA · contact PI
Isolation of the Neuroblastoma Predisposition Gene$290,510
R01 · FY2006 · CA · contact PI
Significance of Genetic Alterations in Neuroblastoma$225,053
R01 · FY2006 · CA · contact PI
Isolation of the Neuroblastoma Predisposition Gene$297,500
R01 · FY2005 · CA
Significance of Genetic Alterations in Neuroblastoma$230,940
R01 · FY2005 · CA
Isolation of the Neuroblastoma Predisposition Gene$297,500
R01 · FY2004 · CA
Significance of Genetic Alterations in Neuroblastoma$237,162
R01 · FY2004 · CA
CHP677: I-MIBG therapy for refractory neuroblastoma: Phase II study$140
M01 · FY2004 · RR
Isolation of the Neuroblastoma Predisposition Gene$297,500
R01 · FY2003 · CA
Significance of Genetic Alterations in Neuroblastoma$239,816
R01 · FY2003 · CA
Significance of Genetic Alterations in Neuroblastoma$255,000
R01 · FY2002 · CA
ISOLATION OF THE NEUROBLASTOMA PREDISPOSITION GENE$254,777
R01 · FY2002 · CA
ISOLATION OF THE NEUROBLASTOMA PREDISPOSITION GENE$0
M01 · FY2002 · RR
BUTHIONINE SUIFOXIMINE IN COMBINATION WITH MELPHALAN FOR PEDIATRIC NEUROBLASTOMA$0
M01 · FY2002 · RR
ISOLATION OF THE NEUROBLASTOMA PREDISPOSITION GENE$247,356
R01 · FY2001 · CA
ISOLATION OF THE NEUROBLASTOMA PREDISPOSITION GENE$240,153
R01 · FY2000 · CA
ISOLATION OF THE NEUROBLASTOMA PREDISPOSITION GENE$0
M01 · FY2000 · RR
BUTHIONINE SUIFOXIMINE IN COMBINATION WITH MELPHALAN FOR PEDIATRIC NEUROBLASTOMA$0
M01 · FY2000 · RR